Health & Medicinearticle2026-11-19

Charcot-Leyden crystals drive a localized inflammatory niche around mucus plugs in Allergic Bronchopulmonary Aspergillosis

Open access0 citations

Abstract

Rationale Mucus plugging causes airflow obstruction, morbidity, and mortality in chronic respiratory diseases. Charcot-Leyden crystals (CLCs), formed from eosinophil-derived Galectin-10, are frequently observed in pathologic mucus, but their role in disease is unclear. Objectives To define the prevalence, inflammatory context, and functional role of CLCs in mucus plugs, using acute allergic bronchopulmonary aspergillosis (ABPA) as a model of eosinophilic muco-obstructive disease. Methods Airway samples from 19 patients with acute ABPA and 61 disease controls were analyzed for CLCs and Galectin-10. Paired samples from plugged and unplugged bronchial mucosal biopsies defined the spatial relationship between CLCs and inflammation. A novel mouse model demonstrated the contribution of CLCs to airway obstruction and inflammation and enabled evaluation of CLC-directed imaging and therapy. Measurements and Main Results Airway CLCs were a sensitive and specific marker of acute ABPA. CLC-containing mucus plugs were surrounded by a localized type 2 inflammatory niche, alongside eosinophils, neutrophils and extracellular traps, whereas inflammation was minimal in unplugged airways from the same patients, or plugs lacking CLCs. In mice, CLC-containing plugs induced persistent airway obstruction and local inflammation, both reduced by a crystal-dissolving anti–Galectin-10 antibody. Galectin-10 concentrations provided a quantitative biomarker of acute ABPA, while a CLC-targeted positron emission tomography tracer enabled noninvasive visualization of crystal-rich plugs. Conclusions CLC-containing mucus plugs form focal inflammatory niches in acute ABPA, and experimental CLC deposition is sufficient to promote persistent airway obstruction and inflammation. These findings identify CLCs as a biomarker, imaging target, and tractable therapeutic target in eosinophilic muco-obstructive airway disease.

// Source

View paper (DOI)Open access versionOpenAlexAmerican Journal of Respiratory and Critical Care MedicinePublished 2026-11-19

Authors: Helena Aegerter, Kenneth Verstraete, Thomas L. A. Malfait, Ines Heyndrickx, Engi Ahmed, Jasmijn Burgelman, Ursula Smole, Hans Ulrichts, Catelijne Stortelers, Siele Ceuppens, Sofie De Prijck, Manon Vanheerswynghels, Sam Dupont, Alysia Wayenberg, Femke Baeke, Amanda Costa Gonçalves, Tania Maes, Leander Jonckheere, Yannick Vande Weygaerde, Heidi Schaballie, Petra Schelstraete, Sebastian Riemann, Guy Brusselle, Richard Hoogenboom, Annemieke Madder, Mélia Magnen, Mark R. Looney, Wilfred W. Raymond, Annabelle R. Charbit, John V. Fahy, Savvas N. Savvides, Eva Van Braeckel, Bart N. Lambrecht

Institutions: KU Leuven, University of California, San Francisco, Ghent University, Inserm, Ghent University Hospital, Centre National de la Recherche Scientifique, University of Bonn, Erasmus University Rotterdam, Erasmus MC, Centre Hospitalier Universitaire de Montpellier, Université de Montpellier, University Hospital Bonn, Université de Reims Champagne-Ardenne, VIB-UGent Center for Plant Systems Biology, VIB-UGent Center for Inflammation Research, Physiologie et Médecine Expérimentale du Coeur et des Muscles, Argenx (Belgium)